Sponsored by
Latest
Topics
Topics
Accounting & Tax
Corporate Finance
Human Capital
Risk & Compliance
Strategy
Technology
Featured
Risk
75% of CFOs Embrace Double Digit Spending Increases
CFOs want to spend more, but access to capital is the challenge, per the CFO Alliance sentiment report.
By
Adam Zaki
| January 26, 2023
Read More
Resources
CFO Live
2022 Survey
Sign Up
Menu
Topics
Accounting & Tax
Corporate Finance
Human Capital
Risk & Compliance
Strategy
Technology
Explore
Search
Latest
Resources
CFO Live
2022 Survey
Sign Up
Sponsored by
pharmaceutical
Risk & Compliance
Kodak Loan Involved No Wrongdoing, DFC Concludes
The company was cleared to receive a $765 million federal loan to make drug ingredients for the U.S. government.
By
Lauren Muskett
| December 7, 2020
Read More
Tech
Amazon Opens Online Pharmacy
“The news represents a disruption to the system and competitive threat that will likely shift scripts away from the retail channel.”
By
Lauren Muskett
| November 17, 2020
Read More
Risk & Compliance
Trump Administration Unveils Deal to Make COVID-19 Drugs in U.S.
The $354 million project is designed to reduce the country's reliance on drugs and pharmaceutical ingredients from foreign manufacturers.
By
Lauren Muskett
| May 19, 2020
Read More
M&A
Eli Lilly to Buy Cancer Drug Specialists Loxo Oncology
In the second major pharmaceutical deal of the year, Eli Lilly will pay about $8 billion for Loxo Oncology.
By
William Sprouse
| January 7, 2019
Read More
M&A
Bristol-Myers to Buy Big Pharma Rival Celgene
The $74 billion deal could create the fourth-largest U.S. pharma firm, with a portfolio that includes nine blockbuster drugs.
By
Matthew Heller
| January 3, 2019
Read More
Financial Performance
New Products Fuel Eli Lilly Q1 Earnings Beat
Drugs such as the diabetes treatment Trulicity "led the company to a strong quarter of volume-driven revenue growth."
By
Matthew Heller
| April 26, 2017
Read More
Strategy
Bayer Discloses $62B Offer for Monsanto
The deal would create the world's largest agricultural supplier but Bayer shareholders fear it will be detrimental to its pharmaceutical business
By
Katie Kuehner-Hebert
| May 23, 2016
Read More
Risk
Mylan to Pay 92% Premium for Sweden’s Meda
After a relentless pursuit, pharmaceutical firm Mylan pays a large premium to acquire a company that sells over-the-counter drugs.
By
Matthew Heller
| February 11, 2016
Read More
Tax
Pfizer Buys Allergan for $160B
The companies predict the combined entity would have more than $25 billion in operating cash flow starting in 2018.
By
Katie Kuehner-Hebert
| November 23, 2015
Read More